Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab second-line in locally advanced or metastatic urothelial or non-urothelial carcinoma
CTR20170412Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in transitional cell carcinoma (TCC), bladder cancer, ureteral cancer, urethral cancer, renal pelvis cancer, sponsored by Roche. Started Jun 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancerureteral cancerurethral cancerrenal pelvis cancer
Beyond the preview
Go deeper on CTR20170412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170412.